Brain fog, missed diagnoses and careers cut short are the symptoms a new European health venture is targeting, arguing that menopause has been treated as an afterthought in clinical research and product design.
The company’s focus sits at the intersection of diagnostics and workplace support, two areas where the menopause market has historically been served by patchy consumer apps rather than clinical-grade tools. Its pitch is that better measurement produces better treatment pathways.
The funding arrives as femtech matures beyond cycle tracking toward conditions that affect older women, a demographic that venture capital has largely overlooked despite its size and spending power. Investors have started to treat the category as a healthcare market rather than a lifestyle niche.
Evidence gaps remain the central obstacle. Hormone therapies and symptom assessment have been understudied for decades, which makes it hard for any company to build a defensible clinical claim on top of thin data.
Several European health systems have begun piloting menopause-specific pathways in primary care, creating a route for tooling that helps clinicians standardize assessment.
The amount raised, the investors and the deployment plan were not disclosed in the report.
